PDL BioPharma, Inc. (PDLI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $3.44, up from yesterday’s close by 1.78%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
Does this stock stack up well when compared to its peers in the industry space? Let’s take a look. PDL BioPharma, Inc. (PDLI) currently trades with a market capitalization of $531.62 Million.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PDLI, the company currently has $349.43 Million of cash on the books, which is offset by $123.79 Million current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $67.85 Million over the past twelve months. Generally speaking, earnings are expected to hold steady in coming quarters. Analysts are forecasting earnings of $0.13 on a per share basis this quarter. Perhaps, that suggests something about why 82.12% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, PDL BioPharma, Inc. recorded a 52-week high of $3.77. It is now trading 0.33% off that level. The stock is trading $2.94 its 50-day moving average by -0.5%. The stock carved out a 52-week low down at $1.93.
In recent action, PDL BioPharma, Inc. (PDLI) has made a move of +12.05% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.36, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 13.28% with $149.86 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PDLI.